123 related articles for article (PubMed ID: 15247138)
1. Irreversible ototoxicity associated with difluoromethylornithine.
Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
[TBL] [Abstract][Full Text] [Related]
2. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia.
Sinicrope FA; Broaddus R; Joshi N; Gerner E; Half E; Kirsch I; Lewin J; Morlan B; Hong WK
Cancer Prev Res (Phila); 2011 Jun; 4(6):829-39. PubMed ID: 21636549
[TBL] [Abstract][Full Text] [Related]
5. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials.
Loprinzi CL; Messing EM; O'Fallon JR; Poon MA; Love RR; Quella SK; Trump DL; Morton RF; Novotny P
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):371-4. PubMed ID: 9162303
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine.
Gerner EW; Garewal HS; Emerson SS; Sampliner RE
Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):325-30. PubMed ID: 8061581
[TBL] [Abstract][Full Text] [Related]
7. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
8. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
[TBL] [Abstract][Full Text] [Related]
9. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
Carbone PP; Pirsch JD; Thomas JP; Douglas JA; Verma AK; Larson PO; Snow S; Tutsch KD; Pauk D
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):657-61. PubMed ID: 11401916
[TBL] [Abstract][Full Text] [Related]
10. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
11. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.
Abeloff MD; Rosen ST; Luk GD; Baylin SB; Zeltzman M; Sjoerdsma A
Cancer Treat Rep; 1986 Jul; 70(7):843-5. PubMed ID: 3013400
[TBL] [Abstract][Full Text] [Related]
12. Delayed, reversible hearing loss caused by difluoromethylornithine (DFMO).
Doyle KJ
Laryngoscope; 2001 May; 111(5):781-5. PubMed ID: 11359155
[TBL] [Abstract][Full Text] [Related]
13. alpha-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results.
Pasic TR; Heisey D; Love RR
Arch Otolaryngol Head Neck Surg; 1997 Dec; 123(12):1281-6. PubMed ID: 9413354
[TBL] [Abstract][Full Text] [Related]
14. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
15. Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer.
Hess LM; Saboda K; Malone DC; Salasche S; Warneke J; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2579-83. PubMed ID: 16284381
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
Meyskens FL; Kingsley EM; Glattke T; Loescher L; Booth A
Invest New Drugs; 1986; 4(3):257-62. PubMed ID: 3102397
[TBL] [Abstract][Full Text] [Related]
17. Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions.
Doyle KJ; McLaren CE; Shanks JE; Galus CM; Meyskens FL
Arch Otolaryngol Head Neck Surg; 2001 May; 127(5):553-8. PubMed ID: 11346432
[TBL] [Abstract][Full Text] [Related]
18. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
[TBL] [Abstract][Full Text] [Related]
19. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
Chow CL; Havighurst T; Lozar T; Jones TD; Kim K; Bailey HH
Laryngoscope; 2023 Mar; 133(3):676-682. PubMed ID: 35620919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
